For research use only. We do not sell to patients.
Ionizable lipids / 6Ac1-C12
6Ac1-C12 structure: six N-methyl tertiary amines; C106H208N6O13
Product imageResearch use only
CAT. NO. DC60809Featured

6Ac1-C12

Pack size & price

USD
TotalUS$600
We match the best price and quality on market.
Ships from ShanghaiIce-pack transportPure lipid recommended
Product overview

Description & Application

6Ac1-C12 is a biodegradable ionizable lipid studied in liver- and lung-directed mRNA-LNPs. Published work distinguishes conventional helper-lipid formulations from simplified lung-directed systems and measures organ accumulation, functional expression and cell-type delivery separately.

Open full Formulation & Performance →

Literature evidence · DC60809

Formulation & Performance

Changing the helper components changes the biological outcome. The liver B-2 formulation and five lung-directed variants are listed separately, with molecular-weight conversions and source-specific measurements.

The current catalog identity is C106H208N6O13, molecular weight 1774.86. Quantitative summaries below were checked against the author Source Data workbook.

Formulation components and molecular-weight conversion

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
6Ac1-C12DC608091774.86150.429402
DOPEDC33634744.03200.240010
CholesterolDCD-041386.65250.155907
DMG-PEG2000DC40169250720.080871

Relative molar parts, not percentages. 6Ac1-C12:mRNA mass ratio 10:1; this is not total lipid:mRNA or N/P. Main p.9; SI pp.2–4. DMG-PEG2000 uses 2507 for the catalog conversion.

Component mass calculator

Prefilled proportions follow the source specified above. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
6Ac1-C12——
DOPE——
Cholesterol——
DMG-PEG2000——

3-Comp Lung (DOTAP)

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
6Ac1-C12DC608091774.86600.878644
DOTAP (chloride)DC33636698.555600.345819
DMG-PEG2000DC4016925071.20.024822

Relative molar parts, not percentages. 6Ac1-C12:mRNA mass ratio 20:1; this is not total lipid:mRNA or N/P. Main p.9; SI p.4. DMG-PEG2000 uses 2507 for the catalog conversion.

Component mass calculator

Prefilled proportions follow the source specified above. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
6Ac1-C12——
DOTAP (chloride)——
DMG-PEG2000——

4-Comp Lung (DOTAP)

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
6Ac1-C12DC608091774.86600.660618
DOTAP (chloride)DC33636698.555600.260008
CholesterolDCD-041386.65400.095943
DMG-PEG2000DC4016925071.20.018663

Relative molar parts, not percentages. A separate lipid:mRNA mass ratio is not assigned here. Main p.9; SI pp.4,21. DMG-PEG2000 uses 2507 for the catalog conversion.

Component mass calculator

Prefilled proportions follow the source specified above. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
6Ac1-C12——
DOTAP (chloride)——
Cholesterol——
DMG-PEG2000——

5-Comp Lung (DOTAP)

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
6Ac1-C12DC608091774.86150.214701
DOPEDC33634744.03200.120005
CholesterolDCD-041386.65250.077954
DMG-PEG2000DC40169250720.040435
DOTAP (chloride)DC33636698.555620.349277

Relative molar parts, not percentages. A separate lipid:mRNA mass ratio is not assigned here. Main pp.9–10; SI p.4. DMG-PEG2000 uses 2507 for the catalog conversion.

Component mass calculator

Prefilled proportions follow the source specified above. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
6Ac1-C12——
DOPE——
Cholesterol——
DMG-PEG2000——
DOTAP (chloride)——

3-Comp Lung (DDAB)

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
6Ac1-C12DC608091774.86500.983847
DDAB (bromide)DC60352630.9525400.279802
DMG-PEG2000DC4016925070.20.005559

Relative molar parts, not percentages. 6Ac1-C12:mRNA mass ratio 20:1; this is not total lipid:mRNA or N/P. Main p.9. DMG-PEG2000 uses 2507 for the catalog conversion.

Component mass calculator

Prefilled proportions follow the source specified above. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
6Ac1-C12——
DDAB (bromide)——
DMG-PEG2000——

4-Comp Lung (DDAB)

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
6Ac1-C12DC608091774.86500.632974
DDAB (bromide)DC60352630.9525400.180015
CholesterolDCD-041386.65500.137892
DMG-PEG2000DC4016925070.20.003576

Relative molar parts, not percentages. A separate lipid:mRNA mass ratio is not assigned here. Main p.9; SI p.20. DMG-PEG2000 uses 2507 for the catalog conversion.

Component mass calculator

Prefilled proportions follow the source specified above. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
6Ac1-C12——
DDAB (bromide)——
Cholesterol——
DMG-PEG2000——

Particle measurements from author Source Data

FormulationSize (nm)PDImRNA binding (%)
Liver B-266.70 ± 0.360.111 ± 0.01785.67 ± 4.16
3-Comp Lung (DOTAP)116.83 ± 1.700.057 ± 0.02195.10 ± 2.35
4-Comp Lung (DOTAP)110.47 ± 1.360.098 ± 0.03196.79 ± 1.48
5-Comp Lung (DOTAP)87.48 ± 3.010.038 ± 0.02090.71 ± 1.81
3-Comp Lung (DDAB)257.13 ± 2.210.134 ± 0.02297.41 ± 2.55

Values are calculated mean ± sample SD, n = 3, from author Source Data: Figure 3 and Supplementary Figs. 9 and 17. The endpoint is mRNA binding efficacy; it has not been relabeled encapsulation efficiency. Different variants are not interchangeable.

Cell studies and delivery mechanism

Study / conditionResultInterpretation
IGROV1 ovarian-cancer cells; 25 ng luciferase mRNA/wellThe B-2 ratio was selected through formulation screeningScreen context, not a clinical dose.
6Ac1-C12 versus double-tail analogueHigher membrane fusion in an endosomal-mimic FRET assayA cell-free mechanism assay, not a measured in vivo escape percentage.
Confocal imaging with labeled mRNAUptake and subsequent intracellular redistribution were observedLabeled-RNA location and translated protein are different endpoints.

Main Figs. 2–3, Methods and Supplementary Fig. 7.

Liver formulation: organ and cell-type delivery

Study / conditionResultInterpretation
B-2; intravenous reporter mRNA; 6 hApproximately 98% of measured organ expression was in liverOrgan luminescence share, not 98% of injected RNA or hepatocytes.
Ai9 Cre reporter mice; 0.25 mg mRNA/kg IV; 48 hApproximately 60% hepatic endothelial-cell transfectionFunctional Cre reporter readout; not the percentage of all liver cells.
Cy5-mRNA distributionEndothelial and Kupffer-cell uptake was observedRNA accumulation does not by itself establish productive translation.

Main Figs. 4–5 and Supplementary Figs. 23–24. Reporter and uptake experiments are kept separate.

Lung formulations: organ accumulation and expression

Study / conditionResultInterpretation
Three-component DOTAP system; luciferase mRNA 0.25 mg/kg IVLung-selective expression and lung-enriched RNA accumulationCholesterol and phospholipid were absent from this formulation.
Three-, four- and five-component comparisonsThree-component DOTAP LNPs outperformed the tested corresponding four-/five-component systems in lung deliveryThis comparison does not rank all possible formulations.
Ai9 Cre reporter; 0.25 mg/kg IV; 48 hApproximately 71% pulmonary endothelial, 34% epithelial and 15% immune cells were reporter-positivePercentages are within each cell population.
DDAB-containing variantsAlso supported lung tropismDDAB particle dimensions differ substantially from DOTAP variants; the results are not pooled.

Main Figs. 4–5; Supplementary Figs. 17, 19–22 and 25–30.

Physical stability and acute tolerability

Study / conditionResultInterpretation
Three-component DOTAP LNP storageParticle size remained broadly unchanged over 30 daysPhysical size stability does not establish retained RNA integrity or full biological potency.
C57BL/6 mice; 0.5 mg mRNA/kg IV; 24 hALT, AST, BUN, creatinine and organ histology were evaluatedAcute single-dose study; PBS and inflammatory positive controls were included.
Reported safety interpretationThe examined liver/lung formulations were well tolerated under these conditionsNo chronic, repeat-dose or human safety claim is inferred.

Main Fig. 5n–o and Supplementary Figs. 31–34.

Original study figures

Organ accumulation, cell-type expression and acute tolerability — Figure 5
Organ accumulation, cell-type expression and acute tolerability — Figure 5
Su et al., Nature Communications (2024), Figure 5, reproduced without content changes under CC BY 4.0; displayed at a responsive size. Panels distinguish labeled-RNA accumulation, Cre-dependent cellular expression, physical stability and acute safety. The figure also contains 5Ac1-C12 comparisons; those results are not reassigned to 6Ac1-C12. See the original caption for n, controls and statistical tests. Original source and caption · CC BY 4.0

References and source locations

  1. Su K, Shi L, Sheng T et al. Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation. Nature Communications 15, 5659 (2024). DOI: 10.1038/s41467-024-50093-7
  2. Author Source Data workbook; particle and biological endpoint data
CAS No.Not available
Chemical Name6Ac1-C12
Synonyms6Ac1C12，， 6Ac1 C12
SMILESCCCCCCCCCCCCN(C)CCC(=O)OCC(COCC(COC(=O)CCN(C)CCCCCCCCCCCC)(COC(=O)CCN(C)CCCCCCCCCCCC)COC(=O)CCN(C)CCCCCCCCCCCC)(COC(=O)CCN(C)CCCCCCCCCCCC)COC(=O)CCN(C)CCCCCCCCCCCC
FormulaC106H208N6O13
M.Wt1774.86
Purity>95% by ELSD-HPLC
StoragePure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping conditionShips from Shanghai. Pure lipid is stable during ice-pack transport.
Publication
  1. Su K, Shi L, Sheng T et al. Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation. Nature Communications 15, 5659 (2024). DOI: 10.1038/s41467-024-50093-7
  2. Author Source Data workbook; particle and biological endpoint data
Laboratory planning

Solution Calculators

Molecular weight 1774.86 g/mol is based on the verified neutral 6Ac1-C12 structure. Calculate final solution volume, concentration or mass; verify complete dissolution.

Mass = concentration × volume × molecular weight
Enter any three values to calculate the fourth.
C₁V₁ = C₂V₂
Enter any three values to calculate the fourth.
Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass1 mM5 mM10 mM
10 mg5.6342 mL1.1268 mL0.5634 mL
25 mg14.0856 mL2.8171 mL1.4086 mL
50 mg28.1712 mL5.6342 mL2.8171 mL
100 mg56.3425 mL11.2685 mL5.6342 mL
250 mg140.8562 mL28.1712 mL14.0856 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Contact us
Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?
We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.
Pure lipid or solution — which should I choose?
Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.
How should I measure a small amount of oily or viscous lipid?
Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.
Can you support formulation optimization and scale-up?
Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.